The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Maxwell Skor - Morgan Stanley - Analyst
: Great. Thank you and congratulations on this milestone. So I have two questions. First question, what are your expectations around patients,
specifically immunocompromised receiving a second dose? Let's say, over a year span, do you expect them to get one dose, two dose, three doses?
And my second question would be, could you elaborate on the anaphylaxis risk and whether you think a lower dose would reduce a patient's
relative risk? Thank you.
Question: Maxwell Skor - Morgan Stanley - Analyst
: Great and congratulations again.
Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst
: Hi, team, congratulations. This is amazing news, and I've got a couple of questions to get a little bit more color on the future plan. Do you plan to
actually submit a full BLA for PEMGARDA? And do you think that future products that might address other viruses, other variants will follow this
accelerated path? Or do you think they will require a different, more traditional BLA path to approval? And then I have a follow-up question.
Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst
: Great. That's really helpful. And regarding addressing new variants, new COVID variants, or even other types of diseases. So going forward, this is
seen as a viral evolution, a platform that addresses viral evolution. Right now, PEMGARDA addresses all the variants. I think you've mentioned that
before. But could you just say -- could you just talk about the high performance with the latest science? Thank you.
Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst
: Thank you.
|
